These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 9002118

  • 21. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
    Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, EPIC Study Group.
    Contemp Clin Trials; 2009 May; 30(3):256-68. PubMed ID: 19470318
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Utility of linezolid in cystic fibrosis].
    Girón-Moreno RM, Ruiz-Velasco LM, Buendía V.
    Enferm Infecc Microbiol Clin; 2004 May; 22(6):369-70. PubMed ID: 15228910
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.
    Padoan R, Cambisano W, Costantini D, Crossignani RM, Danza ML, Trezzi G, Giunta A.
    Pediatr Infect Dis J; 1987 Jul; 6(7):648-53. PubMed ID: 3302917
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Stenvang Pedersen S, Pressler T, Pedersen M, Høiby N, Friis-Møller A, Koch C.
    Scand J Infect Dis; 1986 Jul; 18(2):133-7. PubMed ID: 3518048
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis.
    Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M.
    J Cyst Fibros; 2008 Mar; 7(2):142-6. PubMed ID: 17766190
    [Abstract] [Full Text] [Related]

  • 29. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis.
    Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, Claass A, Broemme S, Jeschke R, Hebestreit A, Staab D, Koetz K, Doering G, Stern M.
    Infection; 2009 Oct; 37(5):418-23. PubMed ID: 19756419
    [Abstract] [Full Text] [Related]

  • 30. Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis.
    Hayes D, Feola DJ, Murphy BS, Kuhn RJ, Davis GA.
    Am J Health Syst Pharm; 2011 Feb 15; 68(4):319-22. PubMed ID: 21289326
    [Abstract] [Full Text] [Related]

  • 31. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL.
    Chest; 2003 May 15; 123(5):1495-502. PubMed ID: 12740266
    [Abstract] [Full Text] [Related]

  • 32. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Jensen T, Pedersen SS, Nielsen CH, Høiby N, Koch C.
    J Antimicrob Chemother; 1987 Oct 15; 20(4):585-94. PubMed ID: 3479420
    [Abstract] [Full Text] [Related]

  • 33. Ciprofloxacin therapy in cystic fibrosis.
    Scully BE, Nakatomi M, Ores C, Davidson S, Neu HC.
    Am J Med; 1987 Apr 27; 82(4A):196-201. PubMed ID: 3555036
    [Abstract] [Full Text] [Related]

  • 34. Use of ciprofloxacin in cystic fibrosis patients.
    Bosso JA.
    Am J Med; 1989 Nov 30; 87(5A):123S-127S. PubMed ID: 2589355
    [Abstract] [Full Text] [Related]

  • 35. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Ryan G, Jahnke N, Remmington T.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD008319. PubMed ID: 23235659
    [Abstract] [Full Text] [Related]

  • 36. Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning.
    Redmond A, Sweeney L, MacFarland M, Mitchell M, Daggett S, Kubin R.
    J Int Med Res; 1998 Dec 12; 26(6):304-12. PubMed ID: 10399112
    [Abstract] [Full Text] [Related]

  • 37. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM, Waugh J, Noble S.
    Drugs; 2003 Dec 12; 63(22):2501-20. PubMed ID: 14609360
    [Abstract] [Full Text] [Related]

  • 38. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
    Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE.
    Lancet Respir Med; 2019 Mar 12; 7(3):213-226. PubMed ID: 30658914
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
    Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F, Zavataro L, Campana S, Italian Group for P aeruginosa Eradication in Cystic Fibrosis.
    Thorax; 2012 Oct 12; 67(10):853-9. PubMed ID: 22379071
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.